David Gerber, MD

Financial relationships

  • Attribution:
    Self
    Type of financial relationship:
    Grant Or Contract
    Ineligible company:
    Karyopharm
    Topic:
    Clinical trial
    Date added:
    Date updated:
    12/29/2023
  • Attribution:
    Self
    Type of financial relationship:
    Grant Or Contract
    Ineligible company:
    BerGenBio
    Topic:
    Clinical trial
    Date added:
    Date updated:
    12/29/2023
  • Attribution:
    Self
    Type of financial relationship:
    Grant Or Contract
    Ineligible company:
    AstraZeneca
    Topic:
    Clinical trial
    Date added:
    Date updated:
    12/29/2023
  • Attribution:
    Self
    Type of financial relationship:
    Grant Or Contract
    Ineligible company:
    Sagimet
    Topic:
    Clinical trial
    Date added:
    Date updated:
    12/29/2023
  • Attribution:
    Self
    Type of financial relationship:
    Stock
    Ineligible company:
    Gilead
    Topic:
    Medicine
    Date added:
    Date updated:
    12/29/2023
  • Attribution:
    Self
    Type of financial relationship:
    Independent contractor
    Ineligible company:
    Catalyst Therapeutics
    Topic:
    Consulting
    Date added:
    Date updated:
    12/29/2023
  • Attribution:
    Self
    Type of financial relationship:
    Independent contractor
    Ineligible company:
    Janssen
    Topic:
    Advisory Board
    Date added:
    Date updated:
    12/29/2023
  • Attribution:
    Self
    Type of financial relationship:
    Independent contractor
    Ineligible company:
    Sanofi
    Topic:
    Advisory Board
    Date added:
    01/03/2022
    Date updated:
    12/29/2023
  • Attribution:
    Self
    Type of financial relationship:
    Independent contractor
    Ineligible company:
    Regeneron
    Topic:
    Advisory Board
    Date added:
    01/03/2022
    Date updated:
    12/29/2023
  • Attribution:
    Self
    Type of financial relationship:
    Stock
    Ineligible company:
    Walgreens
    Topic:
    Pharmacy
    Date added:
    05/16/2023
    Date updated:
    12/29/2023

Pages

Return to 162 Thoracic Oncology Tumor Board Conference (030824)